Abstract
Human ovarian carcinoma parental cells and cisplatin resistant variants were evaluated for the effect of cisplatin on radiosensitization and repair of sublethal radiation damage. The data showed that for 1 h cisplatin treatment (2 mu g/ml), radiosensitization was achieved only if the drug was given after irradiation. Cisplatin treatment was also able to inhibit repair of sublethal radiation damage (SLDR). The degree of inhibition was about the same in the resistant and the sensitive cell lines. In the parental line 4 mu g/ml cisplatin was required to inhibit SLDR while in the resistant line both 2 and 4 mu g/ml produced inhibition of SLDR and in the resistant cell line the degree of SLDR inhibition was greater for cisplatin after irradiation compared to cisplatin before irradiation.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
